This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Icon PLC (ICLR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 1.85% and 1.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -118.75% and 1.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Q4 Earnings Meet Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0% and 0.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Icon PLC (ICLR) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Icon PLC (ICLR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Icon PLC (ICLR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 4.94% and 1.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allscripts (MDRX), CareMetx Tie Up for Better Patient Care
by Zacks Equity Research
Allscripts' (MDRX) Veradigm enters collaboration with CareMetx to streamline specialty medication management for medical clinics and practices across the nation.
Charles River (CRL) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Charles River (CRL) ended the second quarter on a strong note with solid performance by the RMS, DSA and Manufacturing Support arms driving the top line.
Icon PLC (ICLR) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Icon PLC (ICLR) possesses solid growth attributes, which could help it handily outperform the market.
Icon PLC (ICLR) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Surging Earnings Estimates Signal Upside for Icon PLC (ICLR) Stock
by Zacks Equity Research
Icon PLC (ICLR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Top Ranked Growth Stocks to Buy for July 26th
by Zacks Equity Research
ICLR, DG, AN, and DVN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 26, 2021
New Strong Buy Stocks for July 26th
by Zacks Equity Research
CRK, MATX, RGP, ESTE, and ICLR have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2021.
Avantor, Inc. (AVTR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Icon PLC (ICLR) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.95% and 2.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Here is Why Growth Investors Should Buy Icon PLC (ICLR) Now
by Zacks Equity Research
Icon PLC (ICLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Icon PLC (ICLR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys (AMED) Latest New York Assets Buyout Aids Home Health
by Zacks Equity Research
The latest development remains in line with Amedisys' (AMED) ongoing efforts to expand footprint in key markets.
Charles River (CRL) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the RMS, DSA and Manufacturing segments is driving the top line for Charles River (CRL).
LHC Group (LHCG) & SCP Health to Offer Home Health Services
by Zacks Equity Research
LHC Group (LHCG) collaborates with SCP Health to provide innovative and advanced in-home healthcare services.
New Strong Buy Stocks for July 8th
by Zacks Equity Research
MTZ, OLN, CVA, ICLR, and NX have been added to the Zacks Rank #1 (Strong Buy) List on July 8, 2021.
Avantor, Inc. (AVTR) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Icon PLC (ICLR) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Icon PLC (ICLR) could produce exceptional returns because of its solid growth attributes.
Icon PLC (ICLR) Soars 4.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.